Bitcoin Market Faces Volatility Amid New Tariff Measures on Pharmaceuticals

Donald Trump posted claims on Truth Social discussing tariffs, alleged economic growth, and dividends for citizens, raising questions about official economic policies and their validity.

These statements lack official backing, raising skepticism about their authenticity, particularly concerning dividends and economic figures presented without support from formal government communications.

Trump’s 100% Tariff on Non-U.S. Made Pharmaceuticals

In a message shared on Truth Social, Donald Trump declared a 100% tariff on branded pharmaceuticals lacking U.S. manufacturing ties. The aim is to bolster domestic production through these tariffs. This announcement comes amidst broader policy changes announced by the Trump administration, focusing on trade realignment. Immediate market implications are yet to materialize. While no immediate response from major U.S. pharmaceutical firms has been observed, industry experts predict potential shifts in supply chain strategies.

“Trade wars are fought for many reasons, but rarely do they resolve the complexities of global markets,” commented a trade analyst.

“Trade wars are fought for many reasons, but rarely do they resolve the complexities of global markets,” commented a trade analyst.

Global Market and Regulatory Implications of New Tariffs

Did you know? The announcement of tariffs is reminiscent of Trump’s 2018 trade policies, which led to significant market adjustments across different sectors, including pharmaceuticals.

As of November 9, 2025, Bitcoin (BTC) holds a market cap of $2.04 trillion with a price of $102,360.32. Over the past 90 days, BTC experienced a 14.45% decrease. This data, sourced from CoinMarketCap, reflects the ongoing market’s volatility patterns. The Coincu research team anticipates that these tariff actions might spur new regulatory reviews, potentially leading to legal changes affecting pharmaceutical agreements globally.

The Coincu research team anticipates that these tariff actions might spur new regulatory reviews, potentially leading to legal changes affecting pharmaceutical agreements globally.